Aldeyra Therapeutics Enters into a Collaboration with AbbVie to Develop and Commercialize Reproxalap for the Treatment of Dry Eye Disease

Biopharmaceutical Industry Developments

On 01 November 2023, Aldeyra Therapeutics entered into licensing and commercialization agreement with AbbVie. Under the collaboration, AbbVie acquired a an exclusive license to co-develop, manufacture, and commercialize reproxalap for the treatment of patients suffering from dry eye disease. 

Additionally, Aldeyra has received a non-refundable option fee of $1 million and an upfront payment of $100 million less option fees if AbbVie chooses to exercise the option. Further, Aldeyra is eligible to receive up to $300 million in regulatory and commercial milestone payments, inclusive of a $100 million milestone payment after FDA approval of reproxalap in dry eye disease.

According to Roots Analysis, the Dry Eye Diseases Market is anticipated to grow at a stable rate during the forecast period.

For detailed insights about this domain, check out our report on Dry Eye Diseases Market or email sales@rootsanalysis.com

You may also be interested in the following titles: 

1. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030
2. Ocular Drug Delivery System Market, 2021-2030
3. Contact Lenses Market, 2019-2030